Patents Assigned to UCB Biopharma SPRL
  • Fused imidazole and pyrazole derivatives as modulators of TNF activity
    Patent number: 10004737
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 26, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Fused bicyclic heteroaromatic derivatives as kinase inhibitors
    Patent number: 10000497
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 19, 2018
    Assignees: UCB BIOPHARMA SPRL, KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D
    Inventors: Helen Tracey Horsley, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Purine derivatives as modulators of TNF activity
    Patent number: 9988383
    Abstract: A series of substituted purine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: June 5, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Methods of treatment using antibodies which bind IL-17A and IL-17F
    Patent number: 9988446
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: April 20, 2015
    Date of Patent: June 5, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Isoindoline derivatives
    Patent number: 9975873
    Abstract: The present invention relates to isoindoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 22, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: David Skolc, Ali Ates, Eric Jnoff, Anne Valade, Benoit Mathieu, Zara Sands
  • ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF
    Publication number: 20180134774
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Application
    Filed: October 27, 2017
    Publication date: May 17, 2018
    Applicant: UCB Biopharma SPRL
    Inventors: Ralph ADAMS, Pallavi BHATTA, Sam Philip HEYWOOD, David Paul HUMPHREYS
  • Tetrahydroimidazopyridine derivatives as modulators of TNF activity
    Patent number: 9969728
    Abstract: A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-?]pyridine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 15, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Sabine Defays, Jag Paul Heer, Victoria Elizabeth Jackson, James Andrew Johnson, Boris Kroeplien, John Robert Porter
  • Fused bicyclic heteroaromatic derivatives as kinase inhibitors
    Patent number: 9969748
    Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase III? (PI4KIII?) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: May 15, 2018
    Assignees: UCB Biopharma SPRL, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Daniel James Ford, Qiuya Huang, Judi Charlotte Neuss, James Thomas Reuberson, Bart Vanderhoydonck
  • Imidazopyridine derivatives as modulators of TNF activity
    Patent number: 9969729
    Abstract: A series of substituted 1H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 15, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Fabien Claude Lecomte, John Robert Porter
  • ANTI-FCRN ANTIBODIES
    Publication number: 20180127498
    Abstract: The disclosure relates to antibody fusion proteins specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: May 9, 2016
    Publication date: May 10, 2018
    Applicant: UCB Biopharma SPRL
    Inventors: Pallavi BHATTA, Emma DAVE, Sam Philip HEYWOOD, David Paul HUMPHREYS, Bryan John SMITH
  • Isolated DNA sequences encoding, and methods for making, antibody molecules having binding specificity for human IL-13
    Patent number: 9957320
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing antibody molecules.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Neil Gozzard, Alastair David Griffiths Lawson, Daniel John Lightwood, Roger Thomas Palframan, Bryan John Smith, Kerry Louise Tyson
  • Method to generate antibodies to ion channels
    Patent number: 9956274
    Abstract: The present invention provides a method for generating a functionally modifying antibody to an ion channel comprising immunizing a host with a cyclic peptide comprising at least part of an extracellular sequence of said ion channel.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: May 1, 2018
    Assignee: UCB Biopharma SPRL
    Inventor: Terence Seward Baker
  • Benzotriazole derivatives as modulators of TNF activity
    Patent number: 9957255
    Abstract: A series of substituted benzotriazole derivatives, being potent modulators of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Daniel Christopher Brookings, Boris Kroeplien
  • Tetrahydroimidazopyridine derivatives as modulators of TNF activity
    Patent number: 9932334
    Abstract: A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Fused tricyclic benzimidazoles derivatives as modulators of TNF activity
    Patent number: 9932343
    Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Imidazopyrimidine derivatives as modulators of TNF activity
    Patent number: 9932342
    Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Cap for injector
    Patent number: D816834
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Barry Alan Knight, Marko Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
  • Cap for injector
    Patent number: D816835
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: May 1, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Barry Alan Knight, Marko Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
  • Injector
    Patent number: D819804
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: June 5, 2018
    Assignee: UCB Biopharma SPRL
    Inventors: Barry Alan Knight, Marko Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey
  • Injector
    Patent number: D819805
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: June 5, 2018
    Assignee: UCB Biopharma SPRL
    Inventors: Barry Alan Knight, Marko Plevnik, Norihiko Inoue, Jamie Buckley, Lisa Hornsey